biotech · Chronic Hepatitis D Virus (HDV) Infection · Chronic Hepatitis B · VIR
Vir Biotechnology
NovaPharmaNews editorial coverage mentioning Vir Biotechnology — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 1800 Owens St, Suite 900, San Francisco, California 94158, US
- Founded
- 2016
- Employees
- 479
- Programs
- 34
- Drugs
- 17
- Patents
- 6
News & analysis
NovaPharmaNews articles mentioning Vir Biotechnology — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Vir Biotechnology — regulatory, clinical, and market analysis.
Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM
Vir Biotechnology is undergoing significant leadership changes post-AGM, with a board reshuffle and key governance votes set to influence its strategic direction. Investors and pharmaceutical BD teams should monitor these developments for potential shifts in clinical trial focus and market positioning.
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
Gilead Sciences has achieved a significant milestone with the FDA approval of bulevirtide, the first drug to treat chronic hepatitis D. This landmark decision intensifies the competitive landscape as Bay Area rivals Vir Biotechnology and Mirum Pharmaceuticals advance their own therapies.